Purchase the ATMP report at www.evernowpublishing.com

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

GSK buffeted by strong currency

Country: United Kingdom

GlaxoSmithKline Plc ended the first quarter with a decline in sales and operating profit and a portfolio that focuses investment in three areas: pharmaceuticals, vaccines and consumer healthcare. The big event of the quarter was the company’s move to take full control of a joint consumer products venture from Novartis.

Read more

Shire mulls revised Takeda proposal

Country: Ireland

Shire Plc has secured additional time from the UK competition authority to review a proposed bid from Takeda Pharmaceutical Company Ltd that values the Dublin-based company at £46 billion. The parties have until 8 May to reach a decision.

Read more

Novartis reports rise in Q1 sales and profit

Country: Switzerland

Read more

Shire sells oncology assets

Country: Ireland

Read more

Promethera acquires Baliopharm

Country: Belgium

Read more

Funding for lung treatment

Country: United Kingdom

Read more

GSK gene therapy deal

Country: United Kingdom

Read more

Wilson bought by Alexion

Country: Sweden

Read more

GeNeuro targets retrovirus protein in MS

Country: Switzerland

Read more

MorphoSys launches US IPO

Country: Germany

Read more

Combination IO study in melanoma stopped

Country: United States

Read more

Looking for more?

Visit our news section for more articles.

News
Our full Mednous news archive
Appointments
Latest industry appointments
Events
A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

Mitochondrial quality control as potential therapy, by Paul Thompson

MissionTherapeuticsPaulThompsonMar2018.pdf

Highlights of the April 2018 MedNous issue

The April 2018 MedNous features:

Latest Mednous cover
  • Business Strategy
    New approach to atrial fibrillation
    Interview with Acesion Pharma
  • Research Strategy
    How genome editing is impacting cell therapy
    By Jonathan Moore
  • Public Policy
    Non-governmental drug assessments in the US
    By Steven Pearson
  • Health Technology Assessment
    The EU prepares to legislate
    By Karen Finn
  • Business Strategy
    What Roche’s takeover of Flatiron Health really means
    By Tara Raveendran
  • Commentary
    Innate Pharma aims to regain leadership in IO
    By Robin Davison
  • Gene Therapy
    Novartis pays $8.7 billion for AveXis

The latest MedNous journal. Subscribe to download.